| Ytd | 0.62% | |
| 1y | 51.72% |
| Open | 4.79 | Prev Close | 4.73 | Low | 4.75 | High | 4.96 | Mkt Cap | 955.09M |
| Vol | 796.72K | Avg Vol | 1.99M | EPS | 0.83 | P/E | 5.83 | Forward P/E | -9.35 |
| Beta | 1.92 | Short Ratio | 6.50 | Inst. Own | 53.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 4.38 | 200-d Avg | 4.42 | 1yr Est | 5.08 |
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analys
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation s
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data s
U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopha
J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim
Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinica
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdu
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analys
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of Dece
Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor c
Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305
The company will appeal to a federal circuit court to argue that it has limited liability due to its
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust l
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u
Arbutus Biotech faces a pivotal March jury trial against Moderna over LNP patent infringement, creat
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the com
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Modern
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a poten
Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their se
Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared
Arbutus (ABUS) Q2 Revenue Surges 529%
Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Cons
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater C
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Gr
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensu
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to d
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure i
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a
Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at
Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear
Here's a roundup of top developments in the biotech space over the last 24 hours:
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report
During Thursday, 849 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly ea
Following the market opening Wednesday, the Dow traded up 0.99% to 34,824.47 while the NASDAQ climbe
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e
Gainers
Gainers
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report q
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnin